



MARKET RELEASE

30 April 2013


HealthLinx Limited

SUSPENSION FROM OFFICIAL QUOTATION

The securities of HealthLinx Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement.

Security Code: HTX

Kobe Li
Senior Adviser, Listings (Melbourne)



HealthLinx Limited

30 April 2013

ASX Market Announcements
Australian Securities Exchange Limited
Level 4, Rialto,
525 Collins Street,
Melbourne VIC 3000

REQUEST FOR TRADING HALT

In accordance with Listing Rule 17.2 the Company requests voluntary suspension of its securities pending a material announcement. The reasons are:

- The funding facility announced to the market on 21 March 2013 has not eventuated for reasons beyond the control of the Company;
- The Directors are now considering the financial position of the Company and expect to make an announcement in that regard within the next working five days;
- The Company requests that its securities be voluntarily suspended from trading pending a further announcement;
- The Company is not aware of any reason why its securities should not be temporarily suspended.

Mal Lucas-Smith
Company Secretary

About HealthLinx Limited (ASX:HTX)

HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are for diseases with high fatality:

- Ovarian cancer diagnostic (OvPlex) targeting US\$270m pa market
- Prostate cancer targeting US\$350m pa market

A biomarker is a specific biochemical in the body that measures disease or the effects of treatment.

HealthLinx is close to completing the second larger study for OvPlex™ aiming to prove the diagnostic accuracy for ovarian cancer. This larger study is based on approximately 1150 new samples using existing OvPlex™ biomarkers. The study will be a robust comparison of sensitivity and specificity especially for early stage diagnosis in symptomatic women. The objective is to cement the position of OvPlex™ as the world's most accurate and efficient ovarian cancer diagnostic. The second study is partially funded with \$750,000 from the Victorian Government Victoria's Science Agenda Investment Fund.

www.healthlinx.com.au